We came across a bullish thesis on Novo Nordisk A/S (NVO) on Substack by Kontra Investments. In this article, we will ...

Tirzepatide conferred significantly greater weight loss than semaglutide at 72 weeks for adults with overweight or obesity, ...

People taking Eli Lilly's obesity drug, Zepbound, lost nearly 50% more weight than those using rival Novo Nordisk's Wegovy in the first head-to-head study of the blockbuster medications. Clinical ...

On the heels of President Donald Trump’s Monday announcement of an executive order that will slash prescription drug prices ...

For the 2025 outlook, Novo Nordisk now expects 13-21% revenue increase at constant exchange rates (CER). Operating profit is ...

New data suggests the weight-loss drug Wegovy may significantly reduce the risk of heart disease even before users experience ...

Giving obese children weight-loss jabs is effective and helps prevent battles around mealtimes, researchers say. Experts at the European Congress on Obesity in Malaga, Spain, presented findings ...

Within six months, the drug reduced the risk of cardiovascular death by 50 and cut the risk of needing urgent treatment due to heart failure.

Tirzepatide (Zepbound) came out on top against semaglutide (Wegovy) for treating obesity in the head-to-head SURMOUNT-5 trial ...

Tirzepatide slashed weight by 20%, leading researchers to call this a new “golden age” for weight-loss therapies.

A new study found users of one drug lost almost 50 percent more weight that users of Wegovy. People taking Eli Lilly’s ...